Investing.com - Sartorius Stedim reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Sartorius Stedim announced earnings per share of €2.21 on revenue of €862.5M. Analysts polled by Investing.com anticipated EPS of €3.63 on revenue of €774.67M.
Sartorius Stedim shares are down 25% from the beginning of the year and are trading at €361.30 , down-from-52-week-high.They are under-performing the STOXX 600 which is down 5.33% from the start of the year.
Sartorius Stedim shares gained 5.64% in intra-day trade following the report.
Sartorius Stedim follows other major Healthcare sector earnings this month
Sartorius Stedim's report follows an earnings missed by Valneva on Thursday, March 24, 2022, who reported EPS of €0.61 on revenue of €278.3M (NYSE:MMM), compared to forecasts EPS of €0.92 on revenue of €152.55M.
Innate Pharma had beat expectations on Thursday, March 24, 2022 with first quarter EPS of €-0.27 on revenue of €3.81M, compared to forecast for EPS of €-0.32 on revenue of €14.71M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar